Dearborn Partners LLC Cuts Stock Holdings in Stryker Corporation $SYK

Dearborn Partners LLC decreased its position in shares of Stryker Corporation (NYSE:SYK) by 3.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,912 shares of the medical technology company’s stock after selling 3,173 shares during the quarter. Dearborn Partners LLC’s holdings in Stryker were worth $28,438,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SYK. Czech National Bank grew its stake in Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after acquiring an additional 3,366 shares during the period. Davis R M Inc. grew its stake in Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after acquiring an additional 2,512 shares during the period. Kepler Cheuvreux Suisse SA purchased a new stake in Stryker in the 3rd quarter worth approximately $27,952,000. Daymark Wealth Partners LLC grew its stake in Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after acquiring an additional 37,307 shares during the period. Finally, Wealthcare Advisory Partners LLC grew its stake in Stryker by 265.2% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock worth $3,278,000 after acquiring an additional 6,774 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.5%

Shares of NYSE SYK opened at $305.71 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The firm has a fifty day moving average of $318.43 and a 200-day moving average of $345.86. The stock has a market capitalization of $117.20 billion, a PE ratio of 35.38, a P/E/G ratio of 1.93 and a beta of 0.78. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the firm earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s payout ratio is currently 40.74%.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on SYK. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. JPMorgan Chase & Co. cut their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. UBS Group cut their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Finally, Truist Financial reiterated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.